MedWatch

Zealand initiating new diabetes/obesity study

Zealand Pharma is now starting a phase I trial with one of the company’s candidate drugs for diabetes/obesity. Medwatch spoke to the CEO following the news that triggers a milestone payment in the range of millions.

Foto: Zealand Pharma/PR

The Danish biotech company Zealand Pharma continues to thrill investors. As expected, the company is now initiating the first clinical study with its candidate drug ZP2929 for type II diabetes and obesity.

The candidate, which had previously only been tested on animals, has already been administered to the first human test subject, according to a stock market release. It triggers a milestone payment of DKK 37 million from Zealand’s partner, the German pharmaceutical giant Boehringer Ingelheim.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier